Drugs / Insulin glargine/Lixisenatide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05413369 | Jul 2022 → Oct 2023 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine/Lixisenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413369 ↗ |
| Route | Subcutaneous | “Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC)...” NCT05413369 ↗ |